Medical Marijuana in the Pediatric Central Nervous System Tumor Population
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03052738|
Recruitment Status : Recruiting
First Posted : February 14, 2017
Last Update Posted : December 3, 2018
|Condition or disease|
|Central Nervous System Tumor Brain Tumor Spinal Tumor|
Children's Hospital Colorado (CHCO) Center for Cancer and Blood Disorders (CCBD) is a national leader in pediatric cancer therapy. The CHCO Neuro-Oncology program treats more that 90% of Coloradan children with Central Nervous System (CNS) tumors and a large percentage of children with CNS tumors from the surrounding five states. Due to advances in therapy, approximately two-thirds of children with CNS tumors treated at CHCO will be cured. Although medical marijuana has been legal for more than a decade in Colorado, the publicity around the more recent legalization for general adult use, increasing literature, and anecdotal reports of patients with terminal CNS tumors cured with medical marijuana, have prompted a recent increase in interest of current CHCO patients and their families. There has been an influx of pediatric cancer patients and their families moving to Colorado to obtain these marijuana-based products to self-medicate.
The Investigators will administer PedsQLTM questionnaires and diaries to gather data regarding use practices, method of delivery, strain used, dosing and frequency, and family financial impact on all enrolled patients. The Investigators will also collect peripheral blood samples to evaluate for evidence of immuno-modulation by cannabinoids in patients who may already be immunocompromised and to assess blood cannabinoid levels.
This study will provide novel exploratory data regarding use patterns, impact on families and resources, and potential clinical benefits and harms associated with the growing marijuana use in the pediatric neuro-oncology population. Such information may guide future children afflicted with CNS tumors and their families to make decisions about whether to pursue cannabinoid treatment.
|Study Type :||Observational|
|Estimated Enrollment :||150 participants|
|Official Title:||Medical Marijuana in the Pediatric Central Nervous System Tumor Population|
|Actual Study Start Date :||January 15, 2016|
|Estimated Primary Completion Date :||December 2019|
|Estimated Study Completion Date :||December 2019|
- Overall Quality of Life [ Time Frame: 1 year ]quality-of-life scores as assessed by the validated PedsQL™ brain tumor (PedsQL™-BT) module
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03052738
|Contact: Kathleen Dorris, MDfirstname.lastname@example.org|
|Contact: Jessica Channell, BAemail@example.com|
|United States, Colorado|
|Chilsdren's Hospital Colorado||Recruiting|
|Aurora, Colorado, United States, 80045|
|Contact: Kathleen Dorris, MD firstname.lastname@example.org|
|Contact: Jessica Channell, BA email@example.com|
|Principal Investigator:||Nicholas K Foreman, MD||University of Colorado, Denver|